Table 1.
Demographic characteristics and viro-immunological parameters of the patients in study.
| Characteristic | LR (n = 9) |
IR (n = 12) |
HR (n = 9) |
|---|---|---|---|
| Age, years (IQR) | 50 (45–56) | 48 (38–60) | 39 (35–44)a |
| Sex, F (%) | 2 (22) | 3 (25) | 3 (33) |
| Risk factors for HIV infection | |||
| MSM, n (%) heterosexual, n (%) IDU, n (%) |
2 (22) 6 (67) 1 (11) |
5 (42) 4 (33) 3 (25) |
1 (11) 3 (33) 5 (56) |
| Duration of HIV infection, years (IQR) | 7 (5–19) | 13 (8–22) | 12 (6–23) |
| HAART duration, months (IQR) | 71 (46–141) | 106 (65–149) | 71 (39–132) |
| Diagnosis of AIDS, n | 4 | 3 | 2 |
| Absolute T CD4+ cell counts, cell/μL (IQR) | |||
| at the time of study nadir |
260 (215–339) 90 (51–179) |
498 (425–537) 105 (45–208) |
726 (608–863)a
204 (56–240) |
| Percentage T CD4+ cell counts, % (IQR) | |||
| at the time of study nadir |
26 (16–34) 8 (5–17) |
27 (22–33) 18 (13–22) |
31 (25–43) 26 (22–30) |
| Plasma HIV RNA, log10cp/mL (IQR) | |||
| zenith at the time of study |
5.3 (4.5–5.9) 1.7 |
5.4 (4.1–5.7) 1.7 |
4.4 (3.9–5.2) 1.7 |
| HAART regimen Number of patients at the time of study |
|||
| NRTI+PI NRTI+NNRTI Other |
5 2 2 |
7 4 1 |
4 3 2 |
Data are presented as median and interquartile range (IQR). LR: Low Responders (CD4+<350/μL, HIV RNA <40 cp/mL); IR: Intermediate Responders (CD4+ 350–599/μL, HIV RNA <40 cp/mL); HR: High Responders (CD4+ ≥600/μL, HIV RNA <40 cp/mL); MSM: Men having sex with men; IDU: Intravenous Drug Users; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: nonnucleoside reverse-transcriptase inhibitor; PI: protease inhibitor. a P < 0.05 for differences among groups.